Anti-Helicobacter Pylori Concept Stock is Now a Huge Hit

Recently, the news of “Helicobacter pylori is classified as a definite carcinogen in the United States” brought considerable attention to such a bacterium, driving the A-share “anti-Helicobacter pylori concept stocks” to hit limit up. Companies involved include Juneyao Health Drinks, Scitop Biotech, Yatai Pharmaceutical, Jiaoda Onlly, and Guobang Pharma. For instance, Juneyao has exclusive right to use the patent “lactobacillus coelicolor CCFM1118 for the prevention and/or treatment of H. pylori infection”, and Scitop has conducted scientific trials and clinical validation of some probiotic strains on the anti-H. pylori efficacy. (Source: news.qq)